{"id":29292,"date":"2025-03-15T12:39:59","date_gmt":"2025-03-15T04:39:59","guid":{"rendered":"https:\/\/flcube.com\/?page_id=29292"},"modified":"2025-03-15T12:47:17","modified_gmt":"2025-03-15T04:47:17","slug":"feb-2025-fineline-deals-book","status":"publish","type":"page","link":"https:\/\/flcube.com\/?page_id=29292","title":{"rendered":"Feb. 2025 Fineline Deals Book"},"content":{"rendered":"\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>China Pharmaceutical BD Transaction Review &#8211; Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. &#8211; Fineline Deals Book Feb. 2025<\/p>\n<\/blockquote>\n\n\n\n<p class=\"is-style-info\">According to incomplete statistics from Fineline Info &amp; Tech, there were a total of <strong>13<\/strong> pharmaceutical BD and M&amp;A transactions in China in Feb 2025, including <strong>2<\/strong> cross-border asset acquisitions, <strong>7<\/strong> outbound transactions, and <strong>4<\/strong> domestic transactions.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"193\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" src=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png\" alt=\"Fineline Info &amp; Tech\" class=\"wp-image-13755\" srcset=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png 1024w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-300x57.png 300w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-768x145.png 768w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-610x115.png 610w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png 1214w\" \/><\/figure>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/Feb.-2025-Fineline-Deals-Book.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Feb. 2025 Fineline Deals Book.\"><\/object><a id=\"wp-block-file--media-14e9c200-29cb-495c-96d1-da37d26381aa\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/Feb.-2025-Fineline-Deals-Book.pdf\">Feb. 2025 Fineline Deals Book<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/Feb.-2025-Fineline-Deals-Book.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-14e9c200-29cb-495c-96d1-da37d26381aa\">Download<\/a><\/div>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-cross-border-license-in\">Cross-border License In<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p class=\"has-text-align-left\"><a href=\"https:\/\/flcube.com\/?p=21111\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28788\"><br>Baheal Pharmaceutical Gains Exclusive Rights to Roche\u2019s MabThera in China<\/a><\/strong><\/p>\n\n\n\n<p>China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an accord with Roche (SWX: ROG, OTCMKTS: RHHBY), securing exclusive market promotion rights to the Swiss giant\u2019s MabThera (rituximab) in mainland China. Drug ProfileMabThera, the world\u2019s first anti-CD20 monoclonal antibody (mAb), is used to treat Hodgkin\u2026 [<a href=\"https:\/\/flcube.com\/?p=28788\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=28320\">SciClone Pharmaceuticals Licenses Eisai\u2019s Tasurgratinib for China<\/a><\/strong><\/p>\n\n\n\n<p>China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing exclusive development and commercialization rights to the Japanese firm\u2019s tasurgratinib succinate (E7090) in China. Drug ProfileTasurgratinib, an orally available selective inhibitor of FGFR 1-3, was approved in Japan in September of last year. It is\u2026 [<a href=\"https:\/\/flcube.com\/?p=28320\">Full Artical<\/a>]<\/p>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-cross-border-license-out\">Cross-border License Out<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20433\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=25864\"><\/a><a href=\"https:\/\/flcube.com\/?p=29236\"><\/a><a href=\"https:\/\/flcube.com\/?p=25864\">Henlius Biotech Licenses HLX15 to Dr. Reddy\u2019s for US and European Markets<\/a><\/strong><\/p>\n\n\n\n<p>China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy\u2019s Laboratories Ltd. (BOM: 500124) for its HLX15, a biosimilar version of Johnson &amp; Johnson\u2019s Darzalex (daratumumab). Under the agreement, Dr. Reddy\u2019s will obtain exclusive commercialization rights to the anti-CD38 monoclonal antibody (mAb), including both intravenous\u2026 [<a href=\"https:\/\/flcube.com\/?p=25864\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20440\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=29236\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=29236\"><\/a><a href=\"https:\/\/flcube.com\/?p=29236\">Bio-Thera Solutions\u2019 BAT2506 Biosimilar Accepted for Review by China\u2019s NMPA<\/a><\/strong><\/strong><\/p>\n\n\n\n<p>China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a biosimilar version of Johnson &amp; Johnson\u2019s Simponi (golimumab), has been accepted for review by China\u2019s National Medical Products Administration (NMPA). This marks a significant step forward in the development and commercialization of this anti-TNF alpha\u2026[<a href=\"https:\/\/flcube.com\/?p=29236\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28361\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27257\"><\/a><a href=\"https:\/\/flcube.com\/?p=27257\">Beihai Biotech Licenses Beizary to Zydus Lifesciences for US Market<\/a><\/strong><\/p>\n\n\n\n<p>China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the India-headquartered firm exclusive commercialization rights to Beizary, a modified version of docetaxel, in the United States. Deal TermsUnder the agreement, Beihai will handle manufacturing and supply of Beizary. The company will receive an upfront payment\u2026[<a href=\"https:\/\/flcube.com\/?p=27257\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21218\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27250\"><\/a><a href=\"https:\/\/flcube.com\/?p=27250\">PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development<\/a><\/strong><\/p>\n\n\n\n<p>PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a licensing agreement with U.S.-based Photys Therapeutics, Inc. for its HPB-143, a targeted protein degrader (TPD) targeting IRAK4. Under the agreement, Photys will obtain exclusive global development, manufacturing, and commercialization rights to the drug, excluding Greater\u2026 [<a href=\"https:\/\/flcube.com\/?p=27250\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21064\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27333\"><\/a><a href=\"https:\/\/flcube.com\/?p=27333\">CSPC Pharma Licenses SYS 6005 to Radiance Biopharma for Global Markets<\/a><\/strong><\/p>\n\n\n\n<p>China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced a licensing agreement with Radiance Biopharma, Inc., granting the US firm exclusive development and commercialization rights to its SYS 6005 in multiple countries, including the United States, European Union, United Kingdom, Switzerland, Australia, and Canada. Deal TermsUnder the agreement, CSPC Pharma will\u2026[<a href=\"https:\/\/flcube.com\/?p=27333\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28338\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27567\"><\/a><a href=\"https:\/\/flcube.com\/?p=27567\">FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included<\/a><\/strong><\/p>\n\n\n\n<p>US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China subsidiary to UK-based AstraZeneca (NASDAQ: AZN) for approximately USD160 million. The deal includes the transfer of all rights to roxadustat, a treatment for anemia caused by chronic kidney disease (CKD), in China. Transaction DetailsUnder the\u2026 [<a href=\"https:\/\/flcube.com\/?p=27567\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21221\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28235\"><\/a><a href=\"https:\/\/flcube.com\/?p=28235\">EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases<\/a><\/strong><\/p>\n\n\n\n<p>EpimAb Biotherapeutics, Inc. and Medigene AG (ETR: MDG1) today announced a strategic collaboration agreement to research and develop T cell receptor (TCR)-mediated T cell engager therapy (TCR-TCE) for the treatment of immune-related diseases, including solid tumors. Partnership DetailsThe partnership integrates the expertise of both companies across multiple targets. Medigene brings\u2026[<a href=\"https:\/\/flcube.com\/?p=28235\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28371\"><\/a><\/p>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-domestic-transactions-in-china\">Domestic Transactions in China<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20562\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28791\"><\/a><a href=\"https:\/\/flcube.com\/?p=28791\">Lexenpharm and Sun-Novo Partner on Long-Acting Asthma and COPD Drugs<\/a><\/strong><\/p>\n\n\n\n<p>China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) to develop LXP2311 and LXP0531, long-acting drugs targeting asthma and chronic obstructive pulmonary disease (COPD) for the mainland Chinese market. Partnership FocusThe collaboration leverages Lexenpharm\u2019s technical capabilities in respiratory diseases and Sun-Novo\u2019s clinical\u2026 [<a href=\"https:\/\/flcube.com\/?p=28791\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28345\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=29304\"><\/a><a href=\"https:\/\/flcube.com\/?p=29304\">Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development<\/a><\/strong><\/p>\n\n\n\n<p>Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan Kefeng Changjian Pharmaceutical Technology Co., Ltd. (Kefeng Changjian) to advance the development and commercialization of the SPT-07A project. Collaboration DetailsThe agreement, based on the principle of equality and mutual benefit, aims to accelerate the speed\u2026 [<a href=\"https:\/\/flcube.com\/?p=29304\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21475\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27724\"><\/a><a href=\"https:\/\/flcube.com\/?p=27724\">Amoytop Biotech to Acquire Skyline Therapeutics\u2019 Gene Therapy Assets for $15M Plus Milestones<\/a><\/strong><\/p>\n\n\n\n<p>Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of Skyline Therapeutics Limited, a clinical-stage gene therapy developer, excluding its U.S. subsidiary Skyline Therapeutics (US) Inc. The transaction includes a $15 million merger consideration plus up to $43 million in development, sales milestones, sub-license commissions,\u2026[<a href=\"https:\/\/flcube.com\/?p=27724\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21789\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28314\"><\/a><a href=\"https:\/\/flcube.com\/?p=28314\">Sino Biopharmaceutical and Sciwind Biosciences Partner on CPX102 Development<\/a><\/strong><\/p>\n\n\n\n<p>China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced a strategic partnership with compatriot firm Sciwind Biosciences Co., Ltd. The alliance aims to leverage their respective advantageous resources to promote the research and development of CPX102, an interleukin-29 (IL-29) program from Sino Biopharmaceutical. Specifically, the two companies will carry out exclusive licensing\u2026 [<a href=\"https:\/\/flcube.com\/?p=28314\">Full Artical<\/a>]<\/p>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-monthly-roundup\">Monthly Roundup<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p><strong>Key Insights:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cross-Border Deals Surge:<\/strong> China\u2019s pharmaceutical sector saw significant cross-border licensing activity in February 2025, with 9 out of 13 transactions involving international partnerships. This underscores the growing global integration of Chinese biotech firms.<\/li>\n\n\n\n<li><strong>Biosimilars Gain Traction:<\/strong> Biosimilar versions of blockbuster drugs, such as Darzalex and Simponi, were prominent in deals, reflecting the sector\u2019s focus on cost-effective therapies.<\/li>\n\n\n\n<li><strong>Diverse Pipeline Progress:<\/strong> Transactions spanned various stages, from preclinical to market launch, indicating a maturing ecosystem capable of supporting assets through the development lifecycle.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Deal Highlights<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Henlius Biotech\u2019s Darzalex Biosimilar<\/strong><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transaction:<\/strong> Licensed HLX15, a biosimilar of Darzalex, to Dr. Reddy\u2019s Laboratories for $131.6 million.<\/li>\n\n\n\n<li><strong>Implications:<\/strong> Biosimilars continue to drive cross-border interest, with FDA Pipeline I status signaling potential U.S. market entry.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bio-Thera Solutions\u2019 Simponi Biosimilar<\/strong><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transaction:<\/strong> Partnered with Intas Pharmaceuticals for BAT2506, a biosimilar of Simponi, targeting EMA Market Launch.<\/li>\n\n\n\n<li><strong>Analysis:<\/strong> European regulatory pathways are key for Chinese firms to expand their biosimilar footprint globally.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Beihai Biotech\u2019s FDA IND Approval<\/strong><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transaction:<\/strong> Licensed Beizary to Zydus Lifesciences for $168.6 million, including a $25 million upfront payment.<\/li>\n\n\n\n<li><strong>Context:<\/strong> Early-stage assets with FDA IND approval attract partners seeking to fast-track clinical development.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Skyline Therapeutics\u2019 Gene Therapy Deal<\/strong><\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transaction:<\/strong> Granted Amoytop Biotech access to its AAV gene therapy platform for $58 million.<\/li>\n\n\n\n<li><strong>Takeaway:<\/strong> Gene therapy platforms are emerging as high-value assets, with Chinese firms leveraging their technical expertise for global collaborations.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Strategic Implications<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Ambitions Accelerate:<\/strong> Chinese biotechs are increasingly leveraging cross-border deals to commercialize assets in key markets like the U.S. and EU.<\/li>\n\n\n\n<li><strong>Biosimilar Dominance:<\/strong> With biosimilars accounting for nearly 30% of deals, China remains a critical player in the global biosimilar supply chain.<\/li>\n\n\n\n<li><strong>Domestic Consolidation:<\/strong> Local transactions, such as Pharmavan\u2019s SPT-07A deal, highlight efforts to strengthen China\u2019s internal pharma ecosystem through strategic partnerships.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Guidance for Investors and Stakeholders<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Focus on Biosimilars:<\/strong> Track FDA\/EMA filings for biosimilars like HLX15 and BAT2506, as these represent near-term commercialization opportunities.<\/li>\n\n\n\n<li><strong>Early-Stage Assets:<\/strong> Evaluate deals involving preclinical or IND-stage assets (e.g., Beizary, SYS 6005) for high-risk, high-reward potential.<\/li>\n\n\n\n<li><strong>Gene Therapy Platforms:<\/strong> Monitor collaborations like Skyline\u2019s AAV deal, which signal innovation in next-generation therapies.<\/li>\n<\/ol>\n\n\n\n<p><strong>Quote:<\/strong><br>\u201cChina\u2019s pharma sector is rapidly evolving from a domestic focus to a global player, particularly in biosimilars and gene therapy,\u201d said Dr. Emma Zhang, Senior Analyst at Bloomberg Intelligence. \u201cCross-border deals are no longer optional but essential for scaling innovation and accessing mature markets.\u201d<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Next Steps<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Monitor FDA\/EMA approval timelines for key biosimilars and biologics.<\/li>\n\n\n\n<li>Assess partners\u2019 commercialization capabilities in target markets (e.g., Dr. Reddy\u2019s in the U.S., Intas in Europe).<\/li>\n\n\n\n<li>Watch for domestic M&amp;A activity as Chinese firms consolidate their position in the global value chain.<\/li>\n<\/ul>\n\n\n\n<p><em>For more insights, follow <a href=\"https:\/\/flcube.com\">Fineline Info &amp; Tech<\/a><\/em><\/p>\n\n\n\n<p><strong>Previous Recommendations<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=21585\"><\/a><a href=\"https:\/\/flcube.com\/?page_id=28350\">Jan. 2025 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=21585\">Dec. 2024 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=16824\">Nov. 2024 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China Pharmaceutical BD Transaction Review &#8211; Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","footnotes":""},"class_list":["post-29292","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Feb. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fineline Info &amp; Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?page_id=29292\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Feb. 2025 Fineline Deals Book\" \/>\n<meta property=\"og:description\" content=\"Fineline Info &amp; Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?page_id=29292\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-15T04:47:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1214\" \/>\n\t<meta property=\"og:image:height\" content=\"229\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=29292\",\"url\":\"https:\\\/\\\/flcube.com\\\/?page_id=29292\",\"name\":\"Feb. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=29292#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=29292#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02-1024x193.png\",\"datePublished\":\"2025-03-15T04:39:59+00:00\",\"dateModified\":\"2025-03-15T04:47:17+00:00\",\"description\":\"Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=29292#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?page_id=29292\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=29292#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02.png\",\"width\":1214,\"height\":229,\"caption\":\"Fineline Info & Tech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=29292#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Feb. 2025 Fineline Deals Book\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Feb. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry","description":"Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?page_id=29292","og_locale":"en_US","og_type":"article","og_title":"Feb. 2025 Fineline Deals Book","og_description":"Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.","og_url":"https:\/\/flcube.com\/?page_id=29292","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_modified_time":"2025-03-15T04:47:17+00:00","og_image":[{"width":1214,"height":229,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/flcube.com\/?page_id=29292","url":"https:\/\/flcube.com\/?page_id=29292","name":"Feb. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?page_id=29292#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?page_id=29292#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png","datePublished":"2025-03-15T04:39:59+00:00","dateModified":"2025-03-15T04:47:17+00:00","description":"Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.","breadcrumb":{"@id":"https:\/\/flcube.com\/?page_id=29292#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?page_id=29292"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?page_id=29292#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","width":1214,"height":229,"caption":"Fineline Info & Tech"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?page_id=29292#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Feb. 2025 Fineline Deals Book"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/29292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29292"}],"version-history":[{"count":5,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/29292\/revisions"}],"predecessor-version":[{"id":31748,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/29292\/revisions\/31748"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}